Сацитузумаб говитекан

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

91668186

DB12893

Противоопухолевые средства — моноклональные антитела в комбинации с другими препаратами

N (не классифицировано FDA)

1491917-83-9

immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody conjugated to 7-ethyl-10-hydroxycamptothecin (SN-38), active metabolite of irinotecan;
gamma1 heavy chain (1-451) [humanized VH (Homo sapiens IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -Homo sapiens IGHG1*03, Gm3 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345- 449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') - Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (230- 230":233-233")-bisdisulfide; conjugated, on an average of 6 cysteinyl, to 7-ethyl-10-hydroxycamptothecin (SN-38), active metabolite of irinotecan (CPT-11, camptothecin11),via a maleimide-type cleavable linker (carbonate group, self-immolative 4-aminobenzyl alcohol and cathepsine-B-cleavable dipeptide Phe-Lys) and containing a triazoline group and a spacer PEG (n=8).

C₇₆H₁₀₄N₁₂O₂₄S

1601,8 г/моль

Поделиться этой страницей